(firstQuint)A First in Human Study of RT001 in Patients With Friedreich's Ataxia.

 Study RT001-002 is a randomized, double-blind, controlled, ascending dose study to evaluate the safety, tolerability, pharmacokinetic, disease state, and exploratory endpoints in patients with Friedreich's ataxia after oral administration.

 The study includes 2 dose levels of RT001.

.

 A First in Human Study of RT001 in Patients With Friedreich's Ataxia@highlight

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of RT001 in patients with Friedreich's ataxia.

